Last reviewed · How we verify
EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE
EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE is a drug developed by MYLAN. It is currently FDA-approved.
Efavirenz, emtricitabine, and tenofovir alafenamide are used to treat HIV-1 infection. They are a combination of antiretroviral medications that work by inhibiting viral replication.
At a glance
| Generic name | EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE |
|---|---|
| Sponsor | MYLAN |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) Plus a Third Antiretroviral Agent to the Elvitegravi (Phase 3)
- Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum (N/A)
- WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral (Phase 3)
- A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subj (Phase 3)
- Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants (Phase 3)
- Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate to Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 (Phase 4)
- A Phase 3b, Randomized, Open-Label Study to Evaluate Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) (Phase 3)
- Good-first: a Multicohort Study of B/F/TAF As First-line ART in a Public Hospital in Eastern China (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE CI brief — competitive landscape report
- EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE updates RSS · CI watch RSS
- MYLAN portfolio CI
Frequently asked questions about EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE
What is EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE?
EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE is a pharmaceutical drug developed by MYLAN.
Who makes EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE?
EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE is developed and marketed by MYLAN (see full MYLAN pipeline at /company/mylan).
What development phase is EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE in?
EFAVIRENZ, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE is FDA-approved (marketed).
Related
- Manufacturer: MYLAN — full pipeline
- Therapeutic area: All drugs in Other